Diabetes

FDA Approves First Biosimilar Insulin Product

Publish Date August 4, 2021

Semglee (insulin glargine-yfgn) is biosimilar to and interchangeable with Lantus (insulin glargine), provides cost-effective option

Free Fatty Acids Associated With Rapid Decline in Glomerular Filtration Rates in Type 1 Diabetes

Publish Date August 2, 2021

Researchers identified lipidomic predictors of rapid decline of kidney function in individuals with type 1 diabetes.

Antidepressant Use May Aid Outcomes in Depression and Diabetes

Publish Date July 28, 2021

Regular versus poor antidepressant use tied to lower risk for advanced diabetic complications, mortality in patients with depression and diabetes

Cycling Linked to Reduced All-Cause, CVD Mortality in Diabetes

Publish Date July 27, 2021

Multivariable-adjusted hazard ratios for all-cause mortality reduced for 1 to 59, 60 to 149, 150 to 299, and ≥300 minutes/week

Glycemic Control Has Not Been Impacted by Pandemic

Publish Date July 23, 2021

Despite drop in diabetes-related outpatient visits and testing, no negative association found with glycemic control

Dapagliflozin Safe, Effective in Advanced Chronic Kidney Disease

Publish Date July 22, 2021

Dapagliflozin’s benefits among patients with stage 4 CKD were consistent with those observed in the larger DAPA-CKD cohort with stage 2-3 CKD.

High iPTH Linked With Cardiovascular Outcomes in Diabetic Kidney Disease

Publish Date July 21, 2021

Study findings indicate a correlation between iPTH and vascular calcification in patients with diabetic kidney disease.

Glucose-Lowering Therapy Delayed for Newly Diagnosed T2DM Patients

Publish Date July 19, 2021

Factors in therapeutic inertia examined in adults newly diagnosed with T2DM receiving primary care in the U.K.

Patiromer Prolongs Spironolactone Use Regardless of Diabetes Status

Publish Date July 15, 2021

Patient with and without diabetes who received patiromer were more likely to remain on spironolactone at 12 weeks compared with those who received placebo, a subgroup analysis of the AMBER trial showed.

Kerendia Approved to Reduce CKD Progression, CV Risk in Patients With Diabetic Kidney Disease

Publish Date July 14, 2021

The approval was based on data from the phase 3 FIDELIO-DKD trial.